MDY Healthcare set to repay debts and reward shareholders
MDY Healthcare is set to realise its investment in Medivance on the completion of the acquisition of the firm by CR Bard for a total cash consideration of around $250m.
MDY Healthcare is set to realise its investment in Medivance on the completion of the acquisition of the firm by CR Bard for a total cash consideration of around $250m.
The company will receive about £13.98m for its holding in the firm, which it will use to repay all outstanding debt together with all accrued interest.
The firm has so far received £12.80m, with the remaining balance due to be paid
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
within the next 17 months.
It is also the company's intention to return the majority of the funds received to shareholders by the end of March 2012 and said it is in discussions with its advisers on the most efficient and timely way to achieve this.
In a statement the firm said: "The company's strategy going forward is to make further payments to shareholders on receipt of any escrow funds and the realisation, at the appropriate time, of the company's investment in Stanmore."
The share price rose 21.98% to 55.5p by 12:55.
NR
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
Is the Office for National Statistics in turmoil?
Britain’s statistics authority, the Office for National Statistics, is increasingly unfit for purpose. Why, and what can be done?
By Simon Wilson Published
-
Saba Capital and Boaz Weinstein respond to investment trusts
As investment trust managers and industry experts accuse Saba of self-motivated opportunism, the hedge fund responds to specific "misleading claims" and sets out its stall
By Dan McEvoy Published